NEW YORK LIFE INVESTMENT MANAGEMENT LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 256 filers reported holding BRIDGEBIO PHARMA INC in Q2 2024. The put-call ratio across all filers is 0.32 and the average weighting 0.6%.

Quarter-by-quarter ownership
NEW YORK LIFE INVESTMENT MANAGEMENT LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q2 2024$332,228
-8.2%
13,116
+12.0%
0.00%
-25.0%
Q1 2024$362,073
-57.3%
11,710
-44.2%
0.00%
-55.6%
Q4 2023$847,366
+49.9%
20,990
-2.1%
0.01%
+50.0%
Q3 2023$565,373
+32.2%
21,440
-13.7%
0.01%
+50.0%
Q2 2023$427,540
-4.2%
24,857
-7.6%
0.00%
-20.0%
Q1 2023$446,05226,9030.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2024
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$373,797,00067.28%
Darwin Global Management, Ltd. 2,090,149$128,753,00025.21%
Affinity Asset Advisors, LLC 577,500$35,574,00012.08%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$1,913,356,0009.64%
Perceptive Advisors 7,756,928$477,827,0006.04%
Opaleye Management Inc. 583,767$35,960,0005.28%
MIZUHO MARKETS AMERICAS LLC 171,923$10,590,0004.93%
VIKING GLOBAL INVESTORS LP 26,620,991$1,639,853,0004.88%
Fernwood Investment Management, LLC 151,085$9,307,0003.42%
HHLR ADVISORS, LTD. 5,362,014$330,300,0003.26%
View complete list of BRIDGEBIO PHARMA INC shareholders